Targeting cutaneous T‑cell lymphoma in non‑Hodgkin lymphoma: what's new for investigational agents
This review describes the current treatment landscape including underlying disease biology, diagnosis and staging, approaches to therapy with novel FDA‑approved agents including brentuximab vedotin, mogamulizumab, and denileukin diftitox‑cxdl.
Evidence level: Számítógépes vagy elméleti. Modellből vagy adatbányászatból származó jel.
Related signals
- Advanced Classical Hodgkin Lymphoma Management in East and Southeast Asia: Real-World Challenges and Aspirations of the Asian Lymphoma Study Group.
- Overcoming PD‑1 Resistance in Relapsed/Refractory Hodgkin Lymphoma
- Progress in the Treatment of Advanced-Stage Classical Hodgkin Lymphoma in the PET-Adapted Era
- Late cardiopulmonary morbidity in patients with Hodgkin lymphoma: a retrospective nationwide registry study
- Combination of Acimtamig and AlloNK Effective in R/R Classical Hodgkin Lymphoma